Phase 4
N=106
Veteran Stress and Learning Study
Stress Disorders, Posttraumatic
Bottom Line
View on ClinicalTrials.gov: NCT00674570 ↗Enrolled (actual)
106
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) — .0325522; .0245775; -.0181339; .1233174 proportion of max SCR (µS) — p==.66
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Hydrocortisone (Drug); D-Cycloserine (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Jun 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) |
.0325522; .0245775; -.0181339; .1233174; .1024914; .1276977 | =.66 |
Summary
This is a research study examining the use of two medications, Hydrocortisone and D-Cycloserine, compared to an inactive substance (placebo), on their ability to reduce fear responses and memory of fear in Veterans with symptoms of Posttraumatic Stress Disorder (PTSD). These responses will be tested using a fear learning and memory task administered by computer.
Eligibility Criteria
Inclusion Criteria
- Veterans and civilians with an age range of 18 to 65 years
- Participants must be physically healthy volunteers
Exclusion Criteria
- Individuals who fall outside the age range
- Individuals with medical conditions that would interfere with participation
- Other criteria
Data sourced from ClinicalTrials.gov (NCT00674570). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.